<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588702</url>
  </required_header>
  <id_info>
    <org_study_id>CS0817</org_study_id>
    <nct_id>NCT03588702</nct_id>
  </id_info>
  <brief_title>RF and PEMF Following Liposuction</brief_title>
  <official_title>Clinical Evaluation of the Safety and Performance of RF and PEMF Following Liposuction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venus Concept</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Venus Concept</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Venus Legacy LB2 Body applicator is intended for circumference reduction treatment by
      reducing fat cell size and enhancing collagen synthesis as the result of thermal and
      non-thermal collagen stimulation. This is an open-label, evaluator-blind study of the safety
      and performance of radiofrequency (RF) and pulsed electromagnetic field (PEMF) therapy
      following liposuction. The study will enroll up to 50 male and female subjects requesting
      treatment of the back, flanks and/or thighs to improve appearance following liposuction.
      Subjects will receive a total of six study treatments to one side of their body (back, flanks
      and/or thighs) at one week intervals. Subjects will be followed up at one month after their
      last study treatment. Treatment outcomes will be compared to the non-treated side.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adipose tissue is a loose type of connective tissue specialized to store lipids. The majority
      of lipids stored in adipose cells are triglycerides formed from imported free fatty acids and
      glycerol. It is not uniformly distributed in the body. The major adipose depot is
      subcutaneous (about 80% of all body fat).

      The technology options for skin tightening and body contouring have included vacuum massage,
      infrared laser energy, high frequency focused ultrasound, cryolipolysis, radiofrequency
      energy and various hybrid energy device options. Radiofrequency energy devices have remained
      the most common and dominant technology in the noninvasive management of skin tightening,
      cellulite improvement and body contouring enhancement, as they can treat all these conditions
      with relatively consistent results.

      The RF energy is high frequency alternating electrical current that passes into the dermis
      and hypodermal tissues without disruption of the epidermal-dermal barrier. The high frequency
      oscillating electrical current results in collisions between charged molecules and ions and
      the micromolecular mechanical energy from these collisions is transformed into heat. This
      biological RF heat occurs irrespective of chromophore or skin type and is not dependent upon
      selective photothermolysis. The RF heat has different biological and hence, clinical effects,
      depending upon the tissue targeted. In the dermis, where the primary cellular element is the
      fibroblast and the extracellular matrix (ECM) is comprised of collagen, elastin and ground
      substances, the RF mediated thermal stimulation of the ECM results in an immediate and
      temporary shrinkage of the collagen triple helix. Further, the RF thermal stimulation results
      in a microinflammatory stimulation of the fibroblast which in response produces new collagen
      (neocollagenesis) and new elastin neoelastogenesis), and ground substances. RF thermal
      stimulation of adipose tissue results in a thermal mediated stimulation and augmented
      activity of lipase mediated enzymatic degradation of adipocyte derived triglycerides into
      free fatty acids and glycerol. This amplification of the physiologic breakdown and egress of
      the triglycerides out of the adipocyte, while keeping the adipocyte cell membrane and cell
      function intact, results in RF induced shrinkage of the fat cells and body contouring.

      The Venus Legacy LB2 Body Applicator Combines Multi-Polar RF current and Pulsed
      Electromagnetic Fields (PEMF) in synergy with suction/vacuum. PEMF has been shown to increase
      fibroblast derived collagen production through a non-thermal mechanism of membrane
      stimulation, and the stimulation of fibroblast mediated angiogenesis which facilitates and
      enhances wound healing in tissues. Theoretically then, the synergistic RF and PEMF would
      create RF thermal collagen stimulation and PEMF non-thermal stimulation of collagen, RF
      thermally mediated reduction in adipocyte size and PEMF micro-tissue healing effects to
      minimize edema, swelling and downtime that are associated with pure RF thermal therapies.

      The objective of this clinical study is to evaluate the safety and performance of RF and PEMF
      using the Venus Legacy LB2 body applicator following liposuction to the back, flanks and/or
      thighs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects act as their own control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Independent blinded reviewers to view photographs to assess improvement of skin appearance of the treated side at 1 month post-treatment using the General Aesthetic Improvement Scale (GAIS) compared to the non-treated side</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in skin appearance of the treated side</measure>
    <time_frame>One month after last treatment</time_frame>
    <description>Using the General Aesthetic improvement scale (GAIS), blinded reviewers assess photos of liposuction area to determine improvement in treated side as compared to non-treated side where 3 is very much improved; 2 is much improved; 1 is imporved; 0 is no change; -1 is worse; -2 is much worse and -3 is very much worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in skin elasticity of the treated side</measure>
    <time_frame>One month after last treatment</time_frame>
    <description>As measured by a cutometer, determine improvement in skin elasticity of the treated side as compared to the non-treated side where parameter R2, gross elasticity is used. The closer the value is to 1 (100%), the more elastic the skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction of treatment</measure>
    <time_frame>One month after last treatment</time_frame>
    <description>Using the 5-point Likert Satisfaction scale, subjects indicate their satisfaction with the appearance of the treated side as compared to non-treated side where 0 is very unsatisfied; 1 is unsatisfied; 2 is having no opinion; 3 is satisfied and 4 is very satisfied.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lipolysis</condition>
  <arm_group>
    <arm_group_label>Venus Legacy LB2 Body applicator group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RF and PEMF treatment</intervention_name>
    <description>Treatment with Venus Legacy LB2 body applicator</description>
    <arm_group_label>Venus Legacy LB2 Body applicator group</arm_group_label>
    <other_name>Venus Legacy LB2 Body applicator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female older than 18 years of age but not older than 65 years of age.

          2. Having suitable area for treatment (bilateral liposuction of the back, flanks or
             thighs performed 8 weeks prior to study).

          3. BMI score is greater than 18.5 and less than 29.9.

          4. Willingness to refrain from a change in diet/drinking/exercise/medication regimen for
             the entire course of the study.

        Exclusion Criteria:

          1. Pregnant or planning to become pregnant, having given birth (vaginal birth or
             Caesarean surgery) less than 9 months ago, and/or breastfeeding.

          2. Having any active electrical implant anywhere in the body, such as a pacemaker or an
             internal defibrillator.

          3. Having a permanent implant in the treated areas, such as metal plates and screws or an
             injected chemical substance.

          4. Having undergone any other surgery in the treated areas within 9 months of treatment
             or during the study.

          5. Having or undergoing any form of treatment for active cancer, or having a history of
             skin cancer or any other cancer in the areas to be treated, including presence of
             malignant or pre-malignant pigmented lesions.

          6. Suffering from significant concurrent illness, such as cardiac disorders, diabetes
             (type I or II), lupus, porphyria, or pertinent neurological disorders.

          7. Having a known anti-coagulative or thromboembolic condition or taking anticoagulation
             medications one week prior to and during the treatment course.

          8. History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or currently using immunosuppressive medications.

          9. Suffering from hormonal imbalance which may affect weight or cellulite.

         10. History of significant lymphatic drainage problems.

         11. Suffering from significant skin conditions in the treated areas or inflammatory skin
             conditions, including, but not limited to, open lacerations or abrasions and active
             cold sores or herpes sores prior to treatment or during the treatment course.

         12. History of keloid scarring or of abnormal wound healing.

         13. History of being especially prone to bruising.

         14. History of epidermal or dermal disorders (particularly if involving collagen or
             micro-vascularity).

         15. Use of oral retinoids (e.g. isotretinoin (AccutaneÂ®)) within 6 months of treatment or
             during the study.

         16. Use of anti-cellulite creams within a month of treatment or during the course of the
             study.

         17. Significant change in diet or exercise regimen within a month of enrollment or during
             this study and/or weight loss or gain of 10 lbs. (4.5 kgs) within 2 months of
             enrollment or during this study.

         18. Participation in a study of another device or drug within 1 month prior to enrollment
             or during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Cardarelli</last_name>
    <role>Study Director</role>
    <affiliation>Venus Concept</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Biro, MSc</last_name>
    <phone>888-907-0115</phone>
    <phone_ext>132</phone_ext>
    <email>abiro@venusconcept.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louie Cabigao</last_name>
    <phone>888-907-0115</phone>
    <phone_ext>127</phone_ext>
    <email>lcabigao@venusconcept.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ocean Clinic</name>
      <address>
        <city>Marbella</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Garcia Sierra</last_name>
      <phone>(+34) 951 775 518</phone>
      <email>info@oceanclinic.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiofrequency</keyword>
  <keyword>pulsed electro-magnetic fields</keyword>
  <keyword>liposuction</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

